Biopharmaceutical benchmarks 2018

Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Product approvals profile.
Figure 2: Overview of mAb approvals.
Figure 3: Relative use of mammalian- versus nonmammalian-based production cell lines in the manufacture of biopharmaceuticals approved over the indicated periods.

References

  1. 1

    Walsh, G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32, 992–1000 (2014).

  2. 2

    Walsh, G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28, 917–924 (2010).

  3. 3

    Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24, 769–776 (2006).

  4. 4

    La Merie Business Intelligence. http://www.lamerie.com (2018).

  5. 5

    Biosimilars in the EU report: information guide for health professionals. https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf (2017).

  6. 6

    The impact of biosimilar competition on price, volume and market share, June 2016. http://ec.europa.eu/growth/content/impact-biosimilar-competition-price-volume-and-market-share-updated-version-2016-0_en (2016).

  7. 7

    Bertolini, L.R. et al. The transgenic animal platform for biopharmaceutical production. Transgenic Res. 25, 329–343 (2016).

  8. 8

    Park, T.S. et al. Deposition of bioactive human epidermal growth factor in the egg white of transgenic hens using an oviduct-specific minisynthetic promoter. FASEB J. 29, 2386–2396 (2015).

  9. 9

    Miliotou, A.N. & Papadopoulou, L.C. CAR T-cell therapy: a new era in cancer immunotherapy. Curr. Pharm. Biotechnol. 19, 5–18 (2018).

  10. 10

    June, C.H., O'Connor, R.S., Kawalekar, O.U., Ghassemi, S. & Milone, M.C. CAR T cell immunotherapy for human cancer. Science 359, 1361–1365 (2018).

  11. 11

    Kaplon, H. & Reichert, J.M. Antibodies to watch in 2018. MAbs 10, 183–203 (2018).

  12. 12

    FirstWord. Charting the Global Biosimilar Pipeline (FirstWord Publishing, 2018).

  13. 13

    Ginn, S.L., Amaya, A.K., Alexander, I.E., Edelstein, M. & Abedi, M.R. Gene therapy clinical trials worldwide to 2017: an update. J. Gene Med. 20, e3015 (2018).

  14. 14

    Zheng, P.P., Kros, J.M. & Li, J. Approved CAR-T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov. Today 23 1175–1182 (2018).

  15. 15

    Labanieh, L., Majzner, R.G. & Mackall, C.L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377–391 (2018).

  16. 16

    Köhl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29, 559–568 (2018).

  17. 17

    Klinger, M., Benjamin, J., Kischel, R., Stienen, S. & Zugmaier, G. Harnessing T cells to fight cancer with BiTE® antibody constructs—past developments and future directions. Immunol. Rev. 270, 193–208 (2016).

  18. 18

    Trivedi, A. et al. Clinical pharmacology and translational aspects of bispecific antibodies. Clin. Transl. Sci. 10, 147–162 (2017).

Download references

Author information

Correspondence to Gary Walsh.

Supplementary information

Supplementary Table 1

Traditional biotech product approvals 2014–July 2018. (PDF 165 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Walsh, G. Biopharmaceutical benchmarks 2018. Nat Biotechnol 36, 1136–1145 (2018). https://doi.org/10.1038/nbt.4305

Download citation

Further reading